Previous studies have demonstrated that the expression and activation of NF‐κB are strongly induced in the inflamed gut of IBD, and NF‐κB suppression by a pharmacological inhibitor or genetic manipulation could protect against experimental colitis in mice (Hirata et al., 2007). The gene discussed is NFKB1; the disease is colitis.